KEYNOTE-183: A Phase III study of pomalidomide and low-dose dexamethasone with or without pembrolizumab in refractory or relapsed and refractory multiple myeloma.

KEYNOTE-185: A Phase III study of lenalidomide and low-dose dexamethasone with or without pembrolizumab in newly diagnosed and treatment-naïve multiple myeloma.

KEYNOTE-023 Cohort 1: A Phase I multi-cohort trial of pembrolizumab in combination with backbone treatments for subjects with multiple myeloma. Cohort 1 of KEYNOTE-023 evaluated pembrolizumab in combination with lenalidomide and dexamethasone in patients who received prior anti-multiple myeloma treatment with an immunomodulatory (IMiD) treatment (lenalidomide, pomalidomide or thalidomide).

FDA Clinical Hold Hits Keytruda Multiple Myeloma Studies

More from Clinical Trials

More from R&D